Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04879563 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

Study acronym: ASCAPE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Jun 30, 2024 to Aug 30, 2025v5
  2. Primary and study completion dates: Dec 31, 2023 to Jun 30, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 5 of 5 sites
    v4
  3. Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023
    • Site details revised at 3 of 5 sites
    v3
  4. Eligibility criteria shortened, about 3 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.
Trial Details
NCT Number NCT04879563
Lead Sponsor Region Örebro County
Collaborators: UBITECH, ATOS, Siemens Corporation, Corporate Technology, Intrasoft, University of Patras, FORTH - Foundation for Research and Technology Hellas, Sphynx Technology Solutions AG, University of Novi Sad, DFKI - German Research Center for Artificial Intelligence, CareAcross, National and Kapodistrian University of Athens, Fundacio Clinic Barcelona, Arthur's Legal, Fundacion iSYS
Conditions
(from sponsor)		 Breast Cancer, Prostate Cancer, Quality of Life, Survivorship, Toxicity
Related terms Breast Neoplasms, Prostatic Neoplasms
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov